Research Paper Volume 12, Issue 19 pp 19147—19158

BRD4 inhibition sensitizes renal cell carcinoma cells to the PI3K/mTOR dual inhibitor VS-5584

class="figure-viewer-img"

BRD4 is the primary resistance factor of VS-5584 in RCC 786-O cells. In VS-5584-treated stable 786-O cells with BRD4 shRNA (“sh-BRD4-S1/S2”, AC), CRISPR-Cas9-BRD4-KO plasmid (DF) or BRD4-expression vector (“BRD4-GFP”, GI), BRD4, c-Myc and tubulin expression was shown (A, D, G). Cell survival and apoptosis were tested by MTT (after 72 h, B, E, H) and ssDNA ELISA (after 48 h, C, F, I), respectively. The listed proteins were quantified (A, D, G). Data were presented as mean ± standard deviation (SD, n=5). *p< 0.05 vs. “C” group. #p< 0.05.